Table 2. Select pivotal CLL studies with... | American Society of Hematology

Table 2.

Select pivotal CLL studies with venetoclax + anti-CD20 monoclonal antibody

Study	Population	Targeted regimen	Comparator	N (targeted regimen)	ORR, %	CRR, %	uMRD, %	PFS	OS	Notable AEs	Median follow-up, mo
MURANO^37-43	R/R	V-R	BR	194	92	27	62 (^*n = 194) Peripheral blood	53.6 mo	NR (5-y 82.1%)	More grade ≥3 neutropenia with V-R; more grade ≥3 febrile neutropenia and infections with BR	59.2
CLL14^39-44	Treatment naive	V-O	Chl-O	216	85	50	76 (^*n = 216) Peripheral blood	NR (4-y 74%)	NR (4-y 85%)	Grade ≥3 neutropenia (53%) and thrombocytopenia (13%) of V-O	52.4

Study	Population	Targeted regimen	Comparator	N (targeted regimen)	ORR, %	CRR, %	uMRD, %	PFS	OS	Notable AEs	Median follow-up, mo
MURANO^37-43	R/R	V-R	BR	194	92	27	62 (^*n = 194) Peripheral blood	53.6 mo	NR (5-y 82.1%)	More grade ≥3 neutropenia with V-R; more grade ≥3 febrile neutropenia and infections with BR	59.2
CLL14^39-44	Treatment naive	V-O	Chl-O	216	85	50	76 (^*n = 216) Peripheral blood	NR (4-y 74%)	NR (4-y 85%)	Grade ≥3 neutropenia (53%) and thrombocytopenia (13%) of V-O	52.4

^*

Of those evaluable for uMRD in the bone marrow/peripheral blood.

CRR, complete response rate; NR, not reached.